Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
about
Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced NeuropathyA novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cellsNovel quinazolinone MJ-29 triggers endoplasmic reticulum stress and intrinsic apoptosis in murine leukemia WEHI-3 cells and inhibits leukemic miceMicrotubules Negatively Regulate Insulin Secretion in Pancreatic β Cells.Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/AngiogenesisRHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activityA screen for kinetochore-microtubule interaction inhibitors identifies novel antitubulin compoundsUnderstanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulationsA novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclastsThe novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivoStathmin potentiates vinflunine and inhibits Paclitaxel activityThe microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively.1-Oxoeudesm-11(13)-eno-12,8a-lactone induces G2/M arrest and apoptosis of human glioblastoma cells in vitro.Using chemobiosynthesis and synthetic mini-polyketide synthases to produce pharmaceutical intermediates in Escherichia coli.Synthesis and Cytotoxicity Evaluation of C4- and C5-Modified Analogues of the α,β-Unsaturated Lactone of PironetinOrally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinibNeuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysisAntitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer.Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo.Direct interaction between selenoprotein P and tubulinAnaphase-promoting complex/cyclosome protein Cdc27 is a target for curcumin-induced cell cycle arrest and apoptosis.Preclinical profile of cabazitaxel.Herbal medicine as inducers of apoptosis in cancer treatment.Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitorProteomic profiling of rabbit embryonic stem cells derived from parthenotes and fertilized embryos.A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryosSynthesis and SAR studies of novel 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives for anticancer activityIdentification alpha-2-HS-glycoprotein precursor and tubulin beta chain as serology diagnosis biomarker of colorectal cancer.High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics.Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus speciesA genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer.Design and synthesis of imidazo[2,1-b]thiazole-chalcone conjugates: microtubule-destabilizing agents.Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions.Tubulin inhibitor identification by bioactive conformation alignment pharmacophore-guided virtual screening.Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell cultureDesign, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agentsTargeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy.
P2860
Q26747796-B22C16F0-69F7-4480-8EE6-99CF65C27B15Q27302772-85EE2B08-2094-4427-9DB7-F3250ED6B05BQ27303144-1FF0E1E5-8DDE-473A-9F9E-8FC25E24741CQ27314448-84A6C91F-3DF8-4BD1-89C9-00CCEB26F19CQ28077780-25567FB3-88FF-4D16-8142-9763729FA3A1Q28285641-00ABF49C-28E2-45C8-8073-124EC0C80750Q28474838-DDC7C339-C95B-4669-B141-17FE8BC3FA7AQ28482107-47C1CC6B-F976-46D1-996C-2E83527EA66EQ28543087-DEDDD2BF-B183-4BD4-84AC-F63906B59D43Q28545041-4C7A054F-2707-4EE4-B3D5-980E159FA4E4Q28547666-D5FFEA65-9AD8-413E-9702-0920BB931F36Q30511980-BAB4C1AD-524B-4D96-A602-695F45F5B4DFQ33572361-84036DB4-AE00-47A2-BB9D-EA327CEB9074Q33602703-8315442D-189E-431B-9E6D-7829C7CCC2DCQ33628649-149592A6-CB07-4B3B-81ED-DCE42F813206Q33654186-A72E01F7-BF0E-4898-81FD-134CFA86511DQ33815594-8B90CAC4-08A7-4C36-B43D-5E74BE221858Q33822378-36A03581-49EB-4728-A2E6-7C687A5D74A4Q33851448-6B2814CD-0D34-4D1E-B109-9BCADF29E6F3Q33875921-BA713A90-4F91-4976-B476-75E078C46665Q33907716-43C21C60-B62C-4375-8CA1-E5F4F561BFECQ34142043-408D723B-A9C7-42FB-B7FE-C59D254672FBQ34394251-38C269AF-E9EF-41C9-8157-2987EB7184C6Q34424399-42235B7D-3B37-4D1A-9098-00C27CDA419FQ34576078-4F0F73AA-8F97-42EF-91B5-1EB46D777DC7Q34826154-AD848471-2EBD-4FD0-A631-295A73B500D7Q35038184-AA06B5B3-540D-4BEE-99CE-253FF6EEAAE1Q35111443-E662570E-85C7-43AB-AEE2-F6BC9E4986B2Q35117340-F9B2EF16-9816-4485-8A89-298E69562D1BQ35181966-FF6D7AC2-57B1-4A94-9BD1-3D39F969D06DQ35186539-458C4428-71F5-489A-B530-FB8B26386259Q35214605-79D2B58A-3AA4-4612-8C21-63CD789B221CQ35233555-D8F5F43D-DE49-43B1-8FD4-092BFBF32F3CQ35330786-FF1BDBA1-C7CE-4000-9D12-3CBCF121EFE1Q35488032-8F2EC00E-3D08-47F3-9DC2-D6D1FE751250Q35595603-EAEDE50D-FE80-47AC-ACE5-6772E40F582EQ35679369-EEDF3853-7043-43DE-9006-C953ACD82042Q35679387-2C912F62-5501-40F4-84EF-F971B1B2A5CFQ35737288-05CA55E5-88FE-4E0F-92C9-E99C26C7B399Q35762274-80D8095D-3233-4C43-BF1E-9E5E77212FCE
P2860
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@ast
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@en
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@nl
type
label
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@ast
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@en
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@nl
prefLabel
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@ast
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@en
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@nl
P1476
Microtubule inhibitors: Differ ...... ical activity, and resistance.
@en
P2093
Edith A Perez
P304
P356
10.1158/1535-7163.MCT-09-0366
P577
2009-08-11T00:00:00Z